Researchers from the Wellcome Sanger Institute and their collaborators used whole genome sequencing to study when BCR::ABL1—an abnormal fusion of the different genes called BCR and ABL1 ...

Enliven Therapeutics is a clinical-stage concern that has two candidates in its pipeline targeting oncology indications.

BCR::ABL1 is a specific genetic fusion protein that is characteristic of CML, which is created when two genes, BCR and ABL1, become abnormally joined together. With targeted therapy using tyrosine ...

3). Such compounds may potentially be unaffected by mutations of the kinase domain that make BCR–ABL1-positive leukaemic cells resistant to imatinib. Figure 3: Different modes of BCR–ABL binding.

Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, announced the availability of Otsuka Pharmaceutical's third-generation tyrosine kinase inhibitor (TKI ...

Ascentage Pharma Group International’s AAPG share price has surged by 7.56%, which has investors questioning if this is right ...

Full trading is scheduled to start today. Ascentage's lead development asset is olverembatinib, which is the only approved BCR-ABL1 inhibitor in China for patients with chronic phase or ...

Ascentage Pharma (AAPG) announced that two of its proprietary novel drugs have been included in the 2025 Chinese Society of Clinical Oncology, ...

However, despite its well-understood role in CML, little is known about the evolution of this fusion gene, the rate at which cells with BCR::ABL1 start to multiply, and how this contributes to ...

Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, announced the availability ...